In:
Biopharmaceutics & Drug Disposition, Wiley, Vol. 40, No. 3-4 ( 2019-03), p. 151-161
Abstract:
GL‐V9, a derivative of wogonin, has potent anti‐cancer activity. The absorption and metabolism of this compound have not been investigated systematically. This study aims to illustrate the pharmacokinetic characters of GL‐V9 by exploring its metabolic status under different administration routes. To further clarify the absorption mechanism of GL‐V9, an in situ single‐pass perfusion model and a Caco‐2 cell monolayer model were used. Meanwhile, a microsomal incubation system was used to evaluate the enzyme kinetic parameters. In vivo , the obtained gastrointestinal availability (F a × F g ) was 21.28 ± 5.38%. The unmetabolized fraction in the gut wall (F gut wall ) was 98.59 ± 9.74%, while the hepatic bioavailability (F h ) was 29.11 ± 5.22%. These results indicated that poor absorption and extensive metabolism may contribute greatly to the low bioavailability of GL‐V9. The effective permeability (P eff ) in the duodenum and jejunum was 1.34 ± 0.50 × 10 −4 and 0.90 ± 0.27 × 10 −4 cm/s, respectively. The high permeability of GL‐V9 indicated that other unknown factors (such as metabolism) may account for its systemic exposure problem. Studies in rat liver microsomal (RLMs) confirmed this hypothesis, and the Cl int, CYP450s and UGT of GL‐V9 was 0.20 ml/min/mg protein. In conclusion, these results suggest that GL‐V9 possesses higher permeability than wogonin and the metabolism of GL‐V9 is related to its disposition in rat intestine and liver.
Type of Medium:
Online Resource
ISSN:
0142-2782
,
1099-081X
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
1496395-4
SSG:
12
SSG:
15,3
